Report cover image

Orthopedic Biomaterials Market Size, Share & Trends Analysis | United States | 2024-2030 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, Cellular Allografts, and 3 more

Publisher iData Research, Inc.
Published May 29, 2024
Length 388 Pages
SKU # IDR18945065

Description

Orthopedic Biomaterials Market Size, Share & Trends Analysis - United States - 2024-2030 - MedSuite - Includes: Bone Graft Substitutes, Orthopedic Growth Factors, Cellular Allografts, and 3 more


Product Description

In 2023, the U.S. orthopedic biomaterials market was valued at over $5.0 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 5.3%, reaching over $7.2 billion during the forecast period. The comprehensive report on the U.S. market for orthopedic biomaterials covers various segments, including bone graft substitutes (allografts, demineralized bone matrices (DBMs), xenografts, and synthetic bone grafts). The report also encompasses orthopedic growth factors, cellular allografts, orthopedic cell therapy (bone marrow aspirate concentrate and platelet-rich plasma), hyaluronic acid (HA) viscosupplementation (single-, two-, three-, and five-injection cycles), and orthopedic cartilage repair. The cartilage repair segment includes osteochondral allografts, meniscal allografts, autologous chondrocyte implantation, particulated juvenile allografts, and microfracture adjuncts.

DATA TYPES INCLUDED

Unit Sales, Average Selling Prices, Market Value & Growth Trends
Forecasts Until 2030, and Historical Data to 2020
Market Drivers & Limiters for Each Segment
Competitive Analysis with Market Shares for Each Segment
Recent Mergers & Acquisitions
COVID-19 Impact on the Digital Dentistry market
Disease Overviews and Demographic Information
Company Profiles, Product Portfolios and SWOT for Top Competitors

U.S. Orthopedic Biomaterials Market Insights

The orthopedic biomaterials market is heavily influenced by demographic trends, especially the aging population and the increasing incidence of osteoarthritis (OA) in the spine. The rise in spinal fusion procedures is closely linked to the growing number of OA cases, which correlate with advancing age. Since the first wave of baby boomers began retiring in 2008, the population at risk for degenerative diseases has expanded, increasing the demand for treatments such as bone grafts.

As the elderly population continues to grow and obesity rates remain high, the prevalence of degenerative diseases is expected to rise. This demographic shift underscores a heightened need for orthopedic biomaterials and restorative procedures, driving market growth throughout the forecast period.

U.S. Orthopedic Biomaterials Market Share Insights

In the U.S. orthopedic biomaterials market, three main competitors dominate: Medtronic, DePuy Synthes, and Stryker.

Medtronic maintained its leading position in 2023, particularly excelling in the bone graft substitute segment and the growth factor market with its successful INFUSE™ product.

DePuy Synthes held the second-largest market share, a position it has consistently maintained. The company demonstrated significant strength in the bone graft substitute and cellular allograft segments and also distributed the leading hyaluronic acid product. DePuy Synthes offers a demineralized bone matrix (DBM) product processed by the Musculoskeletal Transplant Foundation (MTF) and the DBX® product line, which complements its spinal hardware business. The DBX line includes an osteoinductive and osteoconductive bone graft substitute combined with DBM. Additionally, DePuy Synthes distributes Monovisc® and Orthovisc®, single- and three-injection hyaluronic acid products manufactured by Anika Therapeutics.

Stryker secured the third-largest market share, supported by its extensive product portfolio in the bone graft substitute, growth factor, and cellular allograft markets. This position was largely achieved through strategic acquisitions of several previous competitors.

MARKET SEGMENTATION SUMMARY

U.S. Orthopedic Bone Graft Substitute Market – MedCore – Includes:

Material Type: Autograft, Allograft, Xenograft, Demineralized Bone Matrix, Synthetic.

U.S. Orthopedic Growth Factor Market– MedCore – Includes:

Indication Type: Cervical disc Degeneration, Tibial, Spinal, Ankle & Hindfoot.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cellular Allograft Market– MedCore – Includes:

Anatomy Type: Cervical Spine, Lumbar Spine, Foot & Ankle Allograft, Trauma Allograft.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cell Therapy Market– MedCore – Includes:

Material Type: Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate.

Patient Type: Pediatric/Neonatal, Adult.

U.S. Hyaluronic Acid Viscosupplementation Market – MedCore – Includes:

Injection Cycle Type: Single, Two, Three, Five-Injection.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

U.S. Orthopedic Cartilage Repair Market– MedCore – Includes:

Treatment Type: Microfracture, OATS, Osteochondral Allograft, Meniscal Allograft, Autologous Chondrocyte Implantation, Particulated Juvenile Allograft, Microfracture Adjunct.

Patient Type: Pediatric/Neonatal, Adult.

Care Setting: Hospital, Non-Hospital.

Table of Contents

388 Pages
Chart 1-1: Orthopedic Biomaterials Market by Segment, U.S., 2023 – 2030
Chart 1-2: Orthopedic Biomaterials Market Overview, U.S., 2023 & 2030
Chart 2-1: Multi-Scenario Orthopedic Biomaterials Market Forecast, U.S., 2020 – 2030 (US$M)
Chart 5-1: Orthopedic Biomaterials Market by Segment, U.S., 2020 – 2030
Chart 5-2: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023
Chart 6-1: Orthopedic Biomaterials Procedures by Segment, U.S., 2020 – 2030
Chart 7-1: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 – 2030
Chart 7-2: Orthopedic Bone Graft Substitute Market by Indication, U.S., 2020 – 2030
Chart 7-3: Leading Competitors, Orthopedic Bone Graft Substitute Market, U.S., 2023
Chart 8-1: Orthopedic Growth Factor Market by Segment, U.S., 2020 – 2030
Chart 8-2: Leading Competitors, Orthopedic Growth Factor Market, U.S., 2023
Chart 9-1: Orthopedic Cellular Allograft Market by Segment, U.S., 2020 – 2030
Chart 9-2: Leading Competitors, Orthopedic Cellular Allograft Market, U.S., 2023
Chart 10-1: Orthopedic Cell Therapy Market by Segment, U.S., 2020 – 2030
Chart 10-2: Leading Competitors, Orthopedic Cell Therapy Market, U.S., 2023
Chart 11-1: Hyaluronic Acid (HA) Viscosupplementation Market by Segment, U.S., 2020 – 2030
Chart 11-2: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, U.S., 2023
Chart 12-1: Orthopedic Cartilage Repair Market by Segment, U.S., 2020 – 2030
Chart 12-2: Leading Competitors, Orthopedic Cartilage Repair Market, U.S., 2023
Figure 1-1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2023 (1 of 2)
Figure 1-2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2023 (2 of 2)
Figure 1-3: Companies Researched in This Report
Figure 1-4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2)
Figure 1-5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2)
Figure 1-6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (1 of 6)
Figure 1-7: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (2 of 6)
Figure 1-8: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (3 of 6)
Figure 1-9: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (4 of 6)
Figure 1-10: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (5 of 6)
Figure 1-11: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (6 of 6)
Figure 1-12: Orthopedic Biomaterials Procedures Covered (1 of 4)
Figure 1-13: Orthopedic Biomaterials Procedures Covered (2 of 4)
Figure 1-14: Orthopedic Biomaterials Procedures Covered (3 of 4)
Figure 1-15: Orthopedic Biomaterials Procedures Covered (4 of 4)
Figure 1-16: Procedure Codes Investigated
Figure 1-17: Orthopedic Biomaterials Markets Covered (1 of 6)
Figure 1-18: Orthopedic Biomaterials Markets Covered (2 of 6)
Figure 1-19: Orthopedic Biomaterials Markets Covered (3 of 6)
Figure 1-20: Orthopedic Biomaterials Markets Covered (4 of 6)
Figure 1-21: Orthopedic Biomaterials Markets Covered (5 of 6)
Figure 1-22: Orthopedic Biomaterials Markets Covered (6 of 6)
Figure 1-23: Key Report Updates
Figure 1-24: Version History
Figure 2-1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, U.S., 2020 – 2030 (US$M)
Figure 2-2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, U.S., 2020 – 2030 (US$M)
Figure 2-3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, U.S., 2020 – 2030 (US$M)
Figure 4-1: Bone Graft Substitutes Products by Company (1 of 4)
Figure 4-2: Bone Graft Substitutes Products by Company (2 of 4)
Figure 4-3: Bone Graft Substitutes Products by Company (3 of 4)
Figure 4-4: Bone Graft Substitutes Products by Company (4 of 4)
Figure 4-5: Growth Factor Products by Company
Figure 4-6: Cellular Allograft Products by Company
Figure 4-7: Cell Therapy Products by Company
Figure 4-8: Hyaluronic Acid Viscosupplementation by Products by Company
Figure 4-9: Cartilage Repair Products by Company
Figure 4-10: Class 2 Device Recall GRAFTON DBM (Gel, Flex, Putty, Matrix, Crunch)
Figure 4-11: Class 2 Device Recall GRAFTON PLUS DBM Paste
Figure 4-12: Class 2 Device Recall Magnifuse Bone Graft
Figure 4-13: Class 2 Device Recall Grafton DBF Inject
Figure 4-14: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty
Figure 4-15: Class 2 Device Recall PROSTIM 10cc INJECTABLE
Figure 4-16: Class 2 Device Recall Opteform Allograft Disc
Figure 4-17: Class 2 Device Recall Bioactive Bone Graft Putty
Figure 4-18: Class 3 Device Recall iFACTOR Peptide Enhanced Bone Graft Putty
Figure 4-19: ACDF Using Structural Allograft vs. Tritanium C
Figure 4-20: Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications
Figure 4-21: OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study
Figure 4-22: Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE)
Figure 4-23: Demineralized Bone Matrix Rotator Cuff Study
Figure 4-24: Clinical Outcomes Associated with the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease
Figure 4-25: The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction
Figure 4-26: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft
Figure 4-27: Transforaminal Lumbar Interbody Fusion (TLIF)
Figure 4-28: A Post Market Surveillance on INFUSE Bone Graft
Figure 4-29: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft
Figure 4-30: Evaluation of the Effectiveness of AMPLEX® Compared to Autogenous Bone Grafts
Figure 4-31: Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
Figure 4-32: MagnetOs Putty Compared to Trinity Evolution in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
Figure 4-33: Clinical Outcomes Associated with the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease (ViviGen)
Figure 4-34: Trinity Elite in Lumbar Fusion
Figure 4-35: An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix
Figure 4-36: ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis (ViviGen)
Figure 4-37: Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies
Figure 4-38: Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection
Figure 4-39: BMAC & Allograft vs BMP-2
Figure 4-40: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC)
Figure 4-41: Platelet Rich Plasma in Knee Osteoarthritis
Figure 4-42: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine
Figure 4-43: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain
Figure 4-44: ArtiAid® for Knee Osteoarthritis: A Post-market Study
Figure 4-45: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis
Figure 4-46: Euflexxa for the Treatment of Osteoarthritis
Figure 4-47: MONOVISC for Ankle Joint Pain Relief
Figure 4-48: MONOVISC for Shoulder Joint Pain Relief
Figure 4-49: MONOVISC for Hip Joint Pain Relief
Figure 4-50: Comparison of Hyaluronic Acid and Platelet-Rich Plasma Injections
Figure 4-51: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella
Figure 4-52: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis
Figure 4-53: Phase 2 Clinical Trial of CartiLife® in the United States
Figure 4-54: A Study to Evaluate the Efficacy of BioCartilage® Micronized Cartilage Matrix in Microfracture Treatment of Osteochondral Defects
Figure 5-1: Orthopedic Biomaterials Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 5-2: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023 (1 of 2)
Figure 5-3: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023 (2 of 2)
Figure 5-4: SWOT Analysis, Arthrex
Figure 5-5: SWOT Analysis, Biocomposites
Figure 5-6: SWOT Analysis, Bioventus
Figure 5-7: SWOT Analysis, DePuy Synthes
Figure 5-8: SWOT Analysis, Ferring Pharmaceuticals
Figure 5-9: SWOT Analysis, Isto Biologics
Figure 5-10: SWOT Analysis, Medtronic
Figure 5-11: SWOT Analysis, MTF
Figure 5-12: SWOT Analysis, NuVasive
Figure 5-13: SWOT Analysis, Orthofix
Figure 5-14: SWOT Analysis, Sanofi
Figure 5-15: SWOT Analysis, Stryker
Figure 5-16: SWOT Analysis, Terumo
Figure 5-17: SWOT Analysis, Vericel
Figure 5-18: SWOT Analysis, Zimmer Biomet
Figure 6-1: Procedure Codes Investigated, U.S., 2023
Figure 6-2: Orthopedic Biomaterials Procedures by Segment, U.S., 2020 – 2030
Figure 6-3: Orthopedic Bone Grafting Procedures by Material, U.S., 2020 – 2030
Figure 6-4: Orthopedic Bone Grafting Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-5: Orthopedic Bone Grafting Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-6: Average Units Used per Procedure by Indication, U.S., 2020 – 2030
Figure 6-7: Autograft Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-8: Autograft Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-9: Allograft Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-10: Allograft Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-11: Xenograft Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-12: Xenograft Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-13: DBM Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-14: DBM Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-15: Synthetic Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-16: Synthetic Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-17: Allograft Procedures by Patient Type, U.S., 2020-2030
Figure 6-18: Xenograft Procedures by Patient Type, U.S., 2020-2030
Figure 6-19: DBM Procedures by Patient Type, U.S., 2020-2030
Figure 6-20: Synthetic Procedures by Patient Type, U.S., 2020-2030
Figure 6-21: Orthopedic Bone Grafting Procedures by Care Setting, U.S., 2020-2030
Figure 6-22: Orthopedic Growth Factor Procedures by Indication, U.S., 2020 – 2030
Figure 6-23: Orthopedic Growth Factor Procedures by Care Setting, U.S., 2020 – 2030
Figure 6-24: Cellular Allograft Procedures by Anatomy, U.S., 2020 – 2030
Figure 6-25: Cellular Allograft Procedures by Patient Type, U.S., 2020 – 2030
Figure 6-26: Cellular Allograft Procedures by Care Setting, U.S., 2020 – 2030
Figure 6-27: Orthopedic Cell Therapy Procedures by Material Type, U.S., 2020 – 2030
Figure 6-28: Platelet-Rich Plasma Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-29: Platelet-Rich Plasma Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-30: Bone Marrow Aspirate Concentrate Procedures by Indication, U.S., 2020 – 2030 (1 of 2)
Figure 6-31: Bone Marrow Aspirate Concentrate Procedures by Indication, U.S., 2020 – 2030 (2 of 2)
Figure 6-32: Orthopedic Cell Therapy Procedures by Patient Type, U.S., 2020 – 2030
Figure 6-33: Orthopedic Cell Therapy Procedures by Care Setting, U.S., 2020 – 2030
Figure 6-34: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, U.S., 2020 – 2030 (1 of 2)
Figure 6-35: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, U.S., 2020 – 2030 (2 of 2)
Figure 6-36: Hyaluronic Acid Viscosupplementation Procedures by Patient Type, U.S., 2020 – 2030
Figure 6-37: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, U.S., 2020 – 2030
Figure 6-38: Orthopedic Cartilage Repair Procedures by Type, U.S., 2020 – 2030 (1 of 2)
Figure 6-39: Orthopedic Cartilage Repair Procedures by Type, U.S., 2020 – 2030 (2 of 2)
Figure 6-40: Orthopedic Cartilage Repair Procedures by Patient Type, U.S., 2020 – 2030
Figure 6-41: Orthopedic Cartilage Repair Procedures by Care Setting, U.S., 2020 – 2030
Figure 7-1: Orthopedic Bone Graft Substitute Units per Procedure by Indication, U.S., 2020 – 2030
Figure 7-2: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 7-3: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 7-4: Orthopedic Bone Graft Substitute Market, U.S., 2020 – 2030
Figure 7-5: Allograft Bone Graft Substitute Market, U.S., 2020 – 2030
Figure 7-6: Xenograft Bone Graft Substitute Market, U.S., 2020 – 2030
Figure 7-7: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, U.S., 2020 – 2030
Figure 7-8: Synthetic Bone Graft Substitute Market, U.S., 2020 – 2030
Figure 7-9: Synthetic Bone Graft Substitute Market by Generation Type, U.S., 2020 – 2030 (US$M)
Figure 7-10: Generation 1 Synthetic Bone Graft Substitute Market, U.S., 2020 – 2030
Figure 7-11: Generation 2 Synthetic Bone Graft Substitute Market, U.S., 2020 – 2030
Figure 7-12: Allograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030
Figure 7-13: Spine Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-14: Spine Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030
Figure 7-15: Trauma Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-16: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-17: Allograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030
Figure 7-18: Allograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030
Figure 7-19: Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (1 of 2)
Figure 7-20: Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (2 of 2)
Figure 7-21: Xenograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030
Figure 7-22: Spine Xenograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-23: Spine Xenograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030
Figure 7-24: Trauma Xenograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-25: Large Joint Reconstruction Xenograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-26: Xenograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030
Figure 7-27: Xenograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030
Figure 7-28: Xenograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030
Figure 7-29: DBM with Carriers Market, U.S., 2020-2030
Figure 7-30: DBM without Carriers Market, U.S., 2020-2030
Figure 7-31: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030
Figure 7-32: Spine Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-33: Spine Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030
Figure 7-34: Trauma Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-35: Large Joint Reconstruction Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-36: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030
Figure 7-37: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030
Figure 7-38: Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (1 of 2)
Figure 7-39: Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (2 of 2)
Figure 7-40: Synthetic Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030
Figure 7-41: Spine Synthetic Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-42: Spine Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030
Figure 7-43: Trauma Synthetic Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-44: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold, U.S., 2020 – 2030
Figure 7-45: Synthetic Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030
Figure 7-46: Synthetic Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030
Figure 7-47: Synthetic Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030
Figure 7-48: Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (1 of 2)
Figure 7-49: Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (2 of 2)
Figure 7-50: Leading Competitors, Orthopedic Bone Graft Substitute Market, U.S., 2023
Figure 8-1: Orthopedic Growth Factor Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 8-2: Orthopedic Growth Factor Market, U.S., 2020 – 2030
Figure 8-3: Cervical Disc Degeneration Orthopedic Growth Factor Market, U.S., 2020 – 2030
Figure 8-4: Tibial Fracture Orthopedic Growth Factor Market, U.S., 2020 – 2030
Figure 8-5: Spine Orthopedic Growth Factor Market, U.S., 2020 – 2030
Figure 8-6: Ankle & Hindfoot Fusion Orthopedic Growth Factor Market, U.S., 2020 – 2030
Figure 8-7: Cervical Disc Degeneration Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030
Figure 8-8: Tibial Fracture Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030
Figure 8-9: Spine Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030
Figure 8-10: Ankle and Hindfoot Fusion Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030
Figure 8-11: Leading Competitors, Orthopedic Growth Factor Market, U.S., 2023
Figure 9-1: Orthopedic Cellular Allograft Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 9-2: Orthopedic Cellular Allograft Market, U.S., 2020 – 2030
Figure 9-3: Cervical Spine Orthopedic Cellular Allograft Market, U.S., 2020 – 2030
Figure 9-4: Lumbar Spine Orthopedic Cellular Allograft Market, U.S., 2020 – 2030
Figure 9-5: Foot and Ankle Cellular Allograft Market, U.S., 2020 – 2030
Figure 9-6: Trauma Cellular Allograft Market, U.S., 2020 – 2030
Figure 9-7: Leading Competitors, Orthopedic Cellular Allograft Market, U.S., 2023
Figure 10-1: Orthopedic Cell Therapy Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 10-2: Platelet-Rich Plasma Market, U.S., 2020 – 2030
Figure 10-3: Bone Marrow Aspirate Concentrate Market, U.S., 2020 – 2030
Figure 10-4: Platelet-Rich Plasma Units Sold by Indication Anatomy, U.S., 2020 – 2030
Figure 10-5: Bone Marrow Aspirate Concentrate Units Sold by Indication Anatomy, U.S., 2020 – 2030
Figure 10-6: Leading Competitors, Orthopedic Cell Therapy Market, U.S., 2023
Figure 11-1: Hyaluronic Acid Viscosupplementation Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 11-2: Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030
Figure 11-3: Single-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030
Figure 11-4: Two-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030
Figure 11-5: Three-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030
Figure 11-6: Five-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030
Figure 11-7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, U.S., 2023
Figure 12-1: Orthopedic Cartilage Repair Market by Segment, U.S., 2020 – 2030 (US$M)
Figure 12-2: Osteochondral Allograft Market, U.S., 2020 – 2030
Figure 12-3: Meniscal Allograft Market, U.S., 2020 – 2030
Figure 12-4: Autologous Chondrocyte Implantation Market, U.S., 2020 – 2030
Figure 12-5: Particulated Juvenile Allograft Market, U.S., 2020 – 2030
Figure 12-6: Microfracture Adjunct Market, U.S., 2020 – 2030
Figure 12-7: Osteochondral Allograft Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030
Figure 12-8: Meniscal Allograft Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030
Figure 12-9: Autologous Chondrocyte Implantation Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030
Figure 12-10: Particulated Juvenile Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030
Figure 12-11: Microfracture Adjunct Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030
Figure 12-12: Leading Competitors, Orthopedic Cartilage Repair Market, U.S., 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us